PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
231 hedge funds and large institutions have $1.72B invested in PDL BioPharma, Inc. in 2014 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 78 increasing their positions, 71 reducing their positions, and 29 closing their positions.
38% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 29
22% more capital invested
Capital invested by funds: $1.41B → $1.72B (+$311M)
4% more funds holding
Funds holding: 222 → 231 (+9)
10% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 71
34% less call options, than puts
Call options by funds: $3.82M | Put options by funds: $5.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$21.5M |
| 2 |
QI
QS Investors
New York
|
+$13.7M |
| 3 |
HA
Hays Advisory
Franklin,
Tennessee
|
+$12.1M |
| 4 |
Morgan Stanley
New York
|
+$10.8M |
| 5 |
Renaissance Technologies
New York
|
+$7.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$15.9M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$11.3M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$7.09M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.22M |
| 5 |
CIM
Calvert Investment Management
Bethesda,
Maryland
|
-$4.9M |
PDLI Hedge Fund Activity: Q3 2014 in Review
231 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2014, worth a combined $1.72B — up 22% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new PDLI positions and 29 closed out — a net gain of 11 holders — while 78 added to existing stakes and 71 trimmed.
The largest buyer was Bank of America, adding an estimated $21.5M. The largest seller was Norges Bank, cutting an estimated $15.9M.
- 231 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2014, up from 222 in Q2 2014.
- Funds reported $1.72B of PDL BioPharma, Inc. stock for Q3 2014, up 22% quarter-over-quarter.
- 40 funds opened new PDL BioPharma, Inc. positions in Q3 2014 and 29 closed out, a net change of +11 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2014 was Bank of America, an estimated $21.5M added.
- The largest PDL BioPharma, Inc. seller in Q3 2014 was Norges Bank, an estimated $15.9M sold.
Based on aggregated 13F filings for Q3 2014.